Abstract
Metabolic disease and heart disease are the two most frequent disease combinations with chronic obstructive pulmonary disease (COPD). Endothelial dysfunction and systemic inflammation is an essential component of COPD and metabolic syndrome (MS), which mechanisms of developementand the possibility of pharmacological correctionare studying by scientists.
Objective: To study the effect of statins on endothelial dysfunction in patients with COPD and MS.
Methods. The study involved 33 patients with COPD on second and third stages with MS. Atorvastatin was administered 10 mg once per day for 6 months. The functional state of the endothelium was studied by blood levels of stable metabolites NO (nitrite, nitrate) by Green LC et al, endothelin-1 and the number of circulating desquamatedendothelial cells in blood. Processing of the results was performed using the analysis package in Microsoft Excel program and SPSS 11.0.
Results. Combined treatment with the addition of statin to the therapy schemes causedincreasingof stable metabolitesNO in blood (36%) against a statistically significant reduction in serum ET- 1 (34 %) and decreasing the number of desquamated endothelial cells in blood (28%) of high degree of confidence.
Conclusions. Thus, the decrease of endothelial dysfunction could occur due to the partial removal of the vascular wall inflammation, due to pleiotropic effects of atorvastatin.
- © 2014 ERS